Table II.
Characteristics of non-LC and LC subjects.
| Characteristics | non-LC (n=24, 54.5%) | LC (n=20, 45.5%) | P-valuea |
|---|---|---|---|
| Age (years) | 42.5 (30–60) | 47 (30–68) | 0.4221 |
| Hemophilia A/B (%) | 21 (87.5)/3 (12.5) | 18 (90.0)/2 (10.0) | 0.8284 |
| Prior infection with HBVb (−/+) (%) | 6 (25.0)/18 (75.0) | 7 (35.0)/13 (65.0) | 0.6950 |
| HCV RNA (−/+) | 14 (58.3)/10 (41.7) | 5 (25.0)/15 (75.0) | 0.0552 |
| HIV RNA (−/+) (%) | 20 (83.3)/4 (16.7) | 17 (85.0)/3 (15.0) | 0.7923 |
| WBC (/mm3) | 4,850 (2,900–8,800) | 3,800 (1,800–6,300) | 0.0116 |
| CD4 number (/ml) | 473 (219–1081) | 414.5 (143–544) | 0.1439 |
| CD4% (%) | 30.2 (18.9–44.5) | 29.3 (13.3–46.5) | 0.6290 |
| Hb (g/dl) | 15.0 (10.2–17.4) | 14.4 (8.5–17.1) | 0.2158 |
| Plt (×104/mm3) | 16.9 (6.9–34.9) | 10.7 (4.4–33.1) | 0.0025 |
| PT (%) | 93.5 (69–116) | 74.5 (43–102) | 0.0002 |
| T. bil (mg/dl) | 0.9 (0.4–4.3) | 1.1 (0.4–3.4) | 0.3684 |
| AST (IU/l) | 30.5 (17–173) | 37 (18–82) | 0.2069 |
| ALT (IU/l) | 37.5 (12–183) | 33 (8–87) | 0.7682 |
| Cr (mg/dl) | 0.9 (0.46–1.19) | 0.84 (0.52–10.3) | 0.0504 |
| eGFR (ml/min/1.73 m2) | 71.9 (53.1–157.4) | 77.9 (4.33–138.6) | 0.0677 |
| AFP (ng/dl) | 2.5 (1.5–21.0) | 6.75 (1.6–654.4) | <0.0001 |
| HbA1c (%) | 5.1 (4.3–7.1) | 5.0 (4.4–7.6) | 0.6446 |
| APRI | 0.56 (0.18–3.30) | 0.90 (0.41–3.03) | 0.0196 |
| Fib4 score | 1.45 (0.53–3.43) | 3.35 (0.62–6.69) | 0.0016 |
| IL28Bc (major/minor) (%) | 10 (90.9)/1 (9.1) | 11 (78.6)/3 (21.4) | 0.7751 |
| Previous IFN therapy (−/+) (%) | 9 (37.5)/15 (62.5) | 6 (30.0)/14 (70.0) | 0.8390 |
| Anti-HIV therapy | 0.1753 | ||
| PI plus 2-NRTI | 2 (8.3) | 2 (10.0) | |
| Boosted PI plus 2-NRTI | 6 (25.0) | 9 (45.0) | |
| Boosted PI plus INSTI | 1 (4.2) | 1 (5.0) | |
| Boosted PI plus 2-NRTI and INSTI | 3 (12.5) | 1 (5.0) | |
| INSTI plus 2-NRTI | 4 (16.7) | 3 (15.0) | |
| NNRTI plus 2-NRTI | 2 (8.3) | 2 (10.0) | |
| Others/unknown | 6 (25.0) | 2 (10.0) | |
| TDF containing regimen (−/+) (%) | 16 (66.7)/8 (33.3) | 9 (45.0)/11 (55.0) | 0.1485 |
LC, liver cirrhosis; HBV, hepatitis B virus; WBC, white blood cell; Hb, hemoglobin; Plt, platelet; PT, prothrombin time; T bil, total bilirubin; AST, Aspartate Aminotransferase; ALT, alanine transaminase; Cr, creatinine; eGFR, estimated glomerular filtration rate; AFP, alpha-fetoprotein; HbA1c, glycated hemoglobin A1c; APRI, aspartate transaminase (AST)-platelet ratio index; Fib4 score, Fibrosis-4 score; IL28B, interleukin 28 B; IFN, interferon; PI, protease inhibitors; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; INSTI, integrase strand transfer inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; TDF, tenofovir disoproxil fumarate. Median and range presented, unless otherwise indicated.
P-value was calculated by statistical analysis between HCV non-LC and LC subjects.
Positive for ‘Prior infection with HBV’ indicates positive for any one among HBs antigen, HBs antibody, HBc antibody, and HBe antibody.
IL28B indicated IL28B single-nucleotide polymorphisms (rs8099917).